StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.00−0.08 (-0.44%)

Close on Nov 17, 2026Market cap $2.88BP/E –Yield –

Denali Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Denali Therapeutics's price to book ratio was 3.8× on Nov 11, 2026, against 3.1× a year earlier. Over the last 5 years it ranged from 1.6× to 5.4×, with a median of 3.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.8×+1.2
2025Dec 31, 20252.6×+0.4
2024Dec 31, 20242.2×−0.4
2023Dec 29, 20232.6×−1.6
2022Dec 30, 20224.2×−1.1
2021Dec 31, 20215.4×−6.0
2020Dec 31, 202011.4×+7.6
2019Dec 31, 20193.8×−0.4
2018Dec 31, 20184.2×–

More Denali Therapeutics figures

See a number that looks wrong?